Segment and Geographic Information (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting

The table below is a summary of the segment profit or loss, including significant segment expenses:

	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
	(amounts in thousands)
Revenue	$	181,398	$	100,049	$	302,314	$	180,727
Less:
Cost of services - Molecular profiling services	65,321		59,431		126,215		112,324
Cost of services - Pharma research and development services	2,392		3,064		5,350		4,732
Selling and marketing expense	42,260		38,710		82,089		78,319
General and administrative expense	64,367		41,068		116,486		85,422
Research and development expense	25,047		24,787		48,114		59,164
Interest income	1,618		2,640		2,121		4,408
Interest expense	(19,208)		(13,674)		(31,990)		(22,964)
Changes in fair value of financial instruments	(17,870)		12,000		(50,203)		936
Other expense, net	(18,341)		(141)		(18,358)		(360)
Segment and consolidated net loss	$	(71,790)	$	(66,186)	$	(174,370)	$	(177,214)

Schedule of Revenue by Geographic Areas

The following table sets forth the Company’s revenue by geographic areas based on the customer’s location:

	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
	(amounts in thousands)
United States	$	178,177	$	97,381	$	296,611	$	175,811
International	3,221		2,668		5,703		4,916
Total revenue	$	181,398	$	100,049	$	302,314	$	180,727